Aastrom Biosciences (ASTM) halted news pending
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aastrom (ASTM) Slammed on Staff Cut, New Development Focus
March 27, 2013 9:38 AM EDTAastrom Biosciences, Inc. (Nasdaq: ASTM) shares are getting slammed in early trading Wednesday following an earlier announcement that it would be slashing staff by 50 percent and refocusing resources on development of ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). Shares are down about 30... More
Aastrom Biosciences (ASTM) Announces Major Strategic Change, Slashes Staff by 50%; to Focus on ixmyelocel-T
March 27, 2013 8:49 AM EDTAastrom Biosciences, Inc. (Nasdaq: ASTM) announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). Aastrom, which recently initiated the Phase 2b ixCELL-DCM clinical trial, previously received a U.S. orphan drug designation for the use of ixmyelocel-T in the treatment of DCM. As a result of the strategic change, Aastrom will stop enrollment and end the Phase 3 REVIVE clinical trial in patients with critical limb ischemia (CLI). In addition, the company is executing a corporate... More
